October 20, 2011 (Amsterdam, the Netherlands) — A new investigation finds that 6 years after diagnosis, brain volumes and, particularly, cognition were more severely affected in men with multiple ...

Brain volume loss is a key marker of degeneration in multiple sclerosis, correlated with future disability progression. Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod significantly ...

After menopause, women with multiple sclerosis experienced accelerated volume loss in global gray matter, the left hippocampus, and the left anterior cingulate, highlighting the menopausal transition ...

A cross-sectional, prospective study found that gray matter atrophy was more prevalent in patients with more severe progressive multiple sclerosis (MS) compared with those with less severe progressive ...

"We plan to analyze these MRI structural measures longitudinally to determine if changes in brain volumes or lesion burden over time contribute to fatigue trajectories. More broadly, we might ...

Although a growing body of evidence suggests a positive impact of GLP-1 receptor agonists in treating MS, questions of health ...

Lipoic acid (LA), an oral antioxidant supplement, was not associated with greater improvements in timed walking speed or other clinical outcomes in patients with progressive multiple sclerosis (MS) ...

This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, ...